Monitoring plasma levels of factor Xa inhibitors: How, why and when?

Expert Review of Hematology

Volumn 6, Issue 2, 2013, Pages 155-164

  Samama, Meyer Michel ^a,b   Amiral, Jean ^c   Guinet, Céline ^a   Flem, Léna Le ^a   Seghatchian, Jerard ^d  

^a Biomnis   (France)

^b HÔTEL DIEU   (France)

^c SYSMEX CORPORATION   (Japan)

^d Blood Components Technology and Haemostasis/Thrombosis Consultancy   (United Kingdom)

Author keywords

antifactor Xa; apixaban; calibrators; fondaparinux; heparins; rivaroxaban

Indexed keywords

APIXABAN; BETRIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DANAPAROID; EDOXABAN; ENOXAPARIN; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; TRANSCRIPTION FACTOR IIA;

ANTICOAGULATION; ASSAY; BLOOD SAMPLING; CALIBRATOR; DOSE RESPONSE; DRUG DETERMINATION; ENDOGENOUS ANTI FACTOR 10A ASSAY; ENZYME ACTIVITY; ENZYME INHIBITION; EXOGENOUS ANTI FACTOR 10A ASSAY; HUMAN; INCUBATION TIME; PARTIAL THROMBOPLASTIN TIME; PHYSICIAN; PRIORITY JOURNAL; PROTHROMBIN TIME; QUALITY CONTROL; REVIEW;

ANTICOAGULANTS; BLOOD COAGULATION; DRUG MONITORING; ENZYME ASSAYS; FACTOR XA; HUMANS; PROTEASE INHIBITORS; QUALITY CONTROL;

EID: 84875949506     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.13.11     Document Type: Review

References (31)

1. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G; American College of Chest Physicians. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl.), e44S-e88S (2012).
2. Montoya RC, Gajra A. Current status of new anticoagulants in the management of venous thromboembolism. Adv. Hematol. 2012, 856341 (2012).
3. Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-Analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am. J. Cardiol. 110(3), 453-460 (2012).
4. De Caterina R, Husted S, Wallentin L et al.; Coordinating Committee. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J. Am. Coll. Cardiol. 59(16), 1413-1425 (2012).
5. Garcia DA, Baglin TP, Weitz JI, Samama MM; American College of Chest Physicians. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl.), e24SYe43S (2012).
6. Walenga JM, Jeske WP, Samama MM, Frapaise FX, Bick RL, Fareed J. Fondaparinux: A synthetic heparin pentasaccharide as a new antithrombotic agent. Expert Opin. Investig. Drugs 11(3), 397-407 (2002).
7. Roehrig S, Straub A, Pohlmann J et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]- 1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): An oral, direct factor Xa inhibitor. J. Med. Chem. 48(19), 5900-5908 (2005).
8. Jeske WP, Walenga JM, Samama MM, Hoppensteadt D, Mayuga M, Fareed J. Functionality of fondaparinux (pentasaccharide) depends on clinical antithrombin levels. Blood Coagul. Fibrinolysis 22(3), 206-210 (2011).
9. Walenga JM, Bara L, Samama MM, Fareed J. Amidolytic antifactor Xa assays in the laboratory evaluation of heparin and low molecular weight fractions. Semin. Thromb. Hemost. 11(2), 100-107 (1985).
10. Mani H, Rohde G, Stratmann G et al. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb. Haemost. 108(1), 191-198 (2012).
11. Lindhoff-Last E, Samama MM, Ortel TL, Weitz JI, Spiro TE. Assays for measuring rivaroxaban: Their suitability and limitations. Ther. Drug Monit. 32(6), 673-679 (2010).
12. Samama MM, Amiral J, Guinet C, Perzborn E, Depasse F. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb. Haemost. 104(5), 1078-1079 (2010).
13. Samama MM, Martinoli JL, LeFlem L et al. Assessment of laboratory assays to measure rivaroxaban-An oral, direct factor Xa inhibitor. Thromb. Haemost. 103(4), 815-825 (2010).
14. Castro-López V, Murray B, Harris LF, O'Donnell JS, Killard AJ. Effects of four commercially available factor Xa proteins on the fluorogenic anti-factor Xa assay when monitoring unfractionated heparin. Blood Coagul. Fibrinolysis 23(1), 98-103 (2012).
15. Haas S. Facts and artefacts of coagulation assays for factor Xa inhibitors. Thromb. Haemost. 103(4), 686-688 (2010).
16. Harenberg J, Erdle S, Marx S, Krämer R. Determination of rivaroxaban in human plasma samples. Semin. Thromb. Hemost. 38(2), 178-184 (2012).
17. Asmis LM, Alberio L, Angelillo-Scherrer A et al. Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests: A study in 9 Swiss laboratories. Thromb. Res. 129(4), 492-498 (2012).
18. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin. Pharmacol. Ther. 78(4), 412-421 (2005).
19. Perzborn E, Strassburger J, Wilmen A et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-An oral, direct Factor Xa inhibitor. J. Thromb. Haemost. 3(3), 514-521 (2005).
20. Depasse F, Gerotziafas GT, Busson J, Van Dreden P, Samama MM. Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccharide fondaparinux (Arixtra) anti-Xa activity. J. Thromb. Haemost. 2(2), 346-348 (2004).
21. Samama MM, Contant G, Spiro TE et al.; Rivaroxaban Anti-Factor Xa Chromogenic Assay Field Trial Laboratories. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb. Haemost. 107(2), 379-387 (2012).
22. Harenberg J, Krämer R, Giese C, Marx S, Weiss C, Wehling M. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: Reduction of interassay variability. J. Thromb. Thrombolysis 32(3), 267-271 (2011).
23. Harenberg J, Marx S, Weiss C, Krämer R, Samama MM, Schulman S; Subcommittee on Control of Anticoagulation of the ISTH. Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban. J. Thromb. Haemost. 10(7), 1433-1436 (2012).
24. Bara L, Mardiguian J, Samama M. In vitro effect on Heptest of low molecular weight heparin fractions and preparations with various anti-IIa and anti-Xa activities. Thromb. Res. 57(4), 585-592 (1990).
25. Perzborn E, Harwardt M, Samama MM. Assessment of factor Xa chromogenic assays for measuring the pharmacodynamics of rivaroxaban-An oral, direct factor Xa inhibitor. J. Thromb. Haemost. 7(Suppl. 2), Abstract PP-Mo-185 (2009).
26. Harenberg J, Kraemer R. Measurement of the new anticoagulants. Thromb. Res. 129(Suppl. 1), S106-S113 (2012).
27. Samama MM, Contant G, Spiro TE et al.; Rivaroxaban Prothrombin Time Field Trial Laboratories. Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: Results of a multicenter field trial. Clin. Appl. Thromb. Hemost. 18(2), 150-158 (2012).
28. Sinha U, Lin PH, Edwards ST et al. Inhibition of purified factor Xa amidolytic activity may not be predictive of inhibition of in vivo thrombosis: Implications for identification of therapeutically active inhibitors. Arterioscler. Thromb. Vasc. Biol. 23(6), 1098-1104 (2003).
29. Hacquard M, Perrin J, Lelievre N, Vigneron C, Lecompte T. Inter-individual variability of effect of 7 low molecular weight antithrombin-dependent anticoagulants studied in vitro with calibrated automated thrombography. Thromb. Res. 127(1), 29-34 (2011).
30. Samama MM. Interindividual variability of in vitro response to anticoagulants. Thromb. Res. 127(1), 1 (2011).
31. Ten Cate H. Monitoring new oral anticoagulants, managing thrombosis, or both? Thromb. Haemost. 107(5), 803-805 (2012).